Once-Weekly Exenatide in Youth With Type 2 Diabetes.

Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD

Diabetes care1 Aug 2022Cited by 74 (Europe PMC)

PMID35679098PMCIDPMC9346995DOI10.2337/dc21-2275PepBankPUB-35679098

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In youth with type 2 diabetes, exenatide reduced glycated hemoglobin versus placebo at 24 weeks.
In plain wordsIn youth with type 2 diabetes, exenatide reduced glycated hemoglobin versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlycated hemoglobin
Study
n = 72
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
HbA1c least squares mean change
−0.36%
exenatide
HbA1c least squares mean change
0.49%
placebo
Between-group difference
−0.85%
exenatide versus placebo
Source sentences
Summary
At 24 weeks, the least squares mean change in glycated hemoglobin was -0.36% for the exenatide and +0.49% for the placebo groups (between-group difference, -0.85%; 95% CI -1.51, -0.19; P = 0.012).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively.
Summary · context
The primary efficacy end point was change in glycated hemoglobin from baseline to week 24.
Report a problemFND-3567909801
02HumanRandomized controlled trialEfficacy outcome
In youth with type 2 diabetes, fasting glucose did not differ significantly between exenatide and placebo.
In plain wordsIn youth with type 2 diabetes, fasting glucose did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting glucose
Study
n = 72
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Least squares mean difference from baseline, exenatide versus placebo
−21.6 mg/dL
exenatide versus placebo
Source sentences
Summary
Nonsignificant least squares mean differences from baseline to 24 weeks favoring exenatide were observed: fasting glucose -21.6 mg/dL (-49.0, 5.7; P = 0.119)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively.
Summary · context
The primary efficacy end point was change in glycated hemoglobin from baseline to week 24.
Report a problemFND-3567909802
03HumanRandomized controlled trialEfficacy outcome
In youth with type 2 diabetes, systolic blood pressure did not differ significantly between exenatide and placebo.
In plain wordsIn youth with type 2 diabetes, systolic blood pressure did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSystolic blood pressure
Study
n = 72
Comparator
Placebo
Analysis
Secondary
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Least squares mean difference from baseline, exenatide versus placebo
−2.8 mmHg
exenatide versus placebo
Source sentences
Summary
Nonsignificant least squares mean differences from baseline to 24 weeks favoring exenatide were observed: fasting glucose -21.6 mg/dL (-49.0, 5.7; P = 0.119), systolic blood pressure -2.8 mmHg (-8.0, 2.4; P = 0.284), and body weight -1.22 kg (-3.59, 1.15; P = 0.307).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively.
Summary · context
The primary efficacy end point was change in glycated hemoglobin from baseline to week 24.
Report a problemFND-3567909803
04HumanRandomized controlled trialEfficacy outcome
In youth with type 2 diabetes, body weight did not differ significantly between exenatide and placebo.
In plain wordsIn youth with type 2 diabetes, body weight did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
n = 72
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Least squares mean difference from baseline, exenatide versus placebo
−1.22 kg
exenatide versus placebo
Source sentences
Summary
Nonsignificant least squares mean differences from baseline to 24 weeks favoring exenatide were observed: fasting glucose -21.6 mg/dL (-49.0, 5.7; P = 0.119), systolic blood pressure -2.8 mmHg (-8.0, 2.4; P = 0.284), and body weight -1.22 kg (-3.59, 1.15; P = 0.307).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively.
Summary · context
The primary efficacy end point was change in glycated hemoglobin from baseline to week 24.
Report a problemFND-3567909804
05HumanRandomized controlled trialSafety outcome
In youth with type 2 diabetes, adverse events occurred in 61.0% with exenatide versus 73.9% with placebo.
In plain wordsIn youth with type 2 diabetes, reported adverse events were less frequent with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAdverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Participants with adverse events
36 participants
exenatide
Adverse event incidence
61%
exenatide
Participants with adverse events
17 participants
placebo
Adverse event incidence
73.9%
placebo
Source sentences
Summary
AEs occurred in 36 (61.0%) and 17 (73.9%) participants in the exenatide and placebo groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively.
Summary · context
The primary efficacy end point was change in glycated hemoglobin from baseline to week 24.
Report a problemFND-3567909805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01554618

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

AstraZenecan = 842 Dec 2011 to 5 May 2021

Children and Adolescent With Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 30 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC